{
  "source_file": "07_license_cytodyn.txt",
  "provider": "openai",
  "model": "gpt-5",
  "eval_id": "eval_gpt-5_20251127_164230_96195d38",
  "timestamp": "2025-11-27T16:50:37.498481",
  "extraction": {
    "parties": {
      "raw_snippet": "This Commercialization and License Agreement (this \u201cAgreement\u201d) is made effective as of December 17, 2019 (the \u201cEffective Date\u201d) by and between\nVyera Pharmaceuticals, LLC, a Delaware limited liability company (\u201cVyera\u201d), and CytoDyn Inc., a Delaware corporation (\u201cCytoDyn\u201d).",
      "reasoning": "The introductory paragraph clearly names the contracting entities and their jurisdictions, identifying the two parties to the agreement.",
      "normalized_value": [
        "Vyera Pharmaceuticals, LLC",
        "CytoDyn Inc."
      ]
    },
    "contract_type": {
      "raw_snippet": "2.1 Grant of Licenses.\n(a) License to Vyera. CytoDyn hereby grants to Vyera, and Vyera hereby accepts, an exclusive royalty-bearing license (or sublicense, as the\ncase may be), under the CytoDyn Patents, the CytoDyn Know-How and the Inventions (if any) solely to Commercialize, use, have used,\noffer for sale and sell Licensed Products in the Field in the Territory.",
      "reasoning": "The core substance is an exclusive IP license granting commercialization rights, with royalties and milestones, making this primarily a license agreement despite additional commercialization obligations.",
      "normalized_value": "License Agreement"
    },
    "notice_period": {
      "raw_snippet": "",
      "reasoning": "The agreement does not include an automatic renewal provision; the term ends based on the Royalty Term triggers. Therefore, there is no notice period to prevent an auto-renewal.",
      "normalized_value": ""
    },
    "expiration_date": {
      "raw_snippet": "11.1 Term. The term of this Agreement (\u201cTerm\u201d) shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 11, shall\nexpire on the last day of the Royalty Term.\n\n1.94 \u201cRoyalty Term\u201d means the time period beginning with the First Commercial Sale of the Licensed Product in the Territory and continuing until the\nlatest of (a) the expiration of the last Valid Claim Covering the Licensed Product and included in a CytoDyn Patent licensed to Vyera under this\nAgreement, (b) the date that is ten (10) years from the date of the First Commercial Sale, (c) the expiration of any Regulatory Exclusivity with respect to\nthe Licensed Product and (d) the Biosimilar Entry Date.",
      "reasoning": "Section 11.1 ties expiration to the Royalty Term, and Section 1.94 defines the Royalty Term with relative milestones tied to First Commercial Sale and IP/regulatory events.",
      "normalized_value": "Expires on the last day of the Royalty Term: until the latest of (a) expiration of last Valid Claim; (b) 10 years from First Commercial Sale; (c) expiration of any Regulatory Exclusivity; (d) Biosimilar Entry Date"
    },
    "renewal_term": {
      "raw_snippet": "",
      "reasoning": "No provision states that the agreement auto-renews for successive terms; the duration is tied to the Royalty Term without renewal cycles.",
      "normalized_value": ""
    }
  },
  "usage": {
    "model": "gpt-5-2025-08-07",
    "input_tokens": 35737,
    "output_tokens": 2676
  },
  "latency_seconds": 98.18524289131165
}